Neuronal cytoplasmic and intranuclear aggregates of RNA-binding protein TDP-43 are a hallmark feature of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). ALS and FTLD show a considerable clinical and pathological overlap and occur as both familial and sporadic forms. Though missense mutations in TDP-43 cause rare forms of familial ALS, it is not yet known whether this is due to loss of TDP-43 function or gain of aberrant function. Moreover, the role of wild-type (WT) TDP-43, associated with the majority of familial and sporadic ALS/FTLD patients, is also currently unknown. Generating homozygous and hemizygous WT human TDP-43 transgenic mouse lines, we show here a dosedependent degeneration of cortical and spinal motor neurons and development of spastic quadriplegia reminiscent of ALS. A dosedependent degeneration of nonmotor cortical and subcortical neurons characteristic of FTLD was also observed. Neurons in the affected spinal cord and brain regions showed accumulation of TDP-43 nuclear and cytoplasmic aggregates that were both ubiquitinated and phosphorylated as observed in ALS/FTLD patients. Moreover, the characteristic ≈25-kDa C-terminal fragments (CTFs) were also recovered from nuclear fractions and correlated with disease development and progression in WT TDP-43 mice. These findings suggest that ≈25-kDa TDP-43 CTFs are noxious to neurons by a gain of aberrant nuclear function.
A myotrophic lateral sclerosis (ALS) is one of the most common progressive neuromuscular diseases worldwide and is characterized by degeneration of cortical motor neurons, the motor nuclei of the brainstem, and the anterior horn cells of the spinal cord. Dysfunction and death of these neurons lead to muscle weakness, atrophy, and spasticity (1) . Frontotemporal lobar degeneration (FTLD) is the second most common form of cortical dementia in the presenium, accounting for ≈20% of dementia patients in this age group (2) . Both ALS and FTLD patients are characterized by ubiquitinated neuronal cytoplasmic and intranuclear inclusions (NCIs and NIIs) in affected brain regions (2) . Approximately 20% of patients with ALS show frontal lobe dysfunction that overlaps with the pathology of FTLD, suggesting that FTLD and ALS are part of the same disease spectrum (3) .
The recent identification of the TAR DNA-binding protein-43 (TDP-43) as a major protein constituent of NCIs and NIIs in ALS and FTLD (FTLD-U or FTLD-TDP) patients has offered a molecular link between these two disorders (4, 5) . TDP-43 is a 414-amino acid protein with two highly conserved RNA recognition motifs (RRM1 and RRM2), a nuclear localization signal (NLS) at the protein N-terminus, and a glycine-rich region mediating protein-protein interactions at the C-terminus (6) (7) (8) (9) . Pathological TDP-43 is abnormally ubiquitinated, hyperphosphorylated, and N-terminally cleaved to generate CTFs (4, 5) .
Missense mutations in the TDP-43 gene (TARDBP), mostly in the C-terminal glycine-rich region, have been identified in patients with ALS (10, 11) , and ALS associated with FTLD (12) . However, in FTLD and in the majority of familial and sporadic ALS patients, no TARDBP mutations are identified, suggesting that wild-type (WT) TDP-43 is central to the disease cascade (9, 13) . Recently, overexpression of the TDP-43 homolog in yeast or injections of viral hTDP-43 constructs in the substantia nigra of rats have been shown to cause cell death (14, 15) . To identify neurons specifically vulnerable to increased TDP-43 levels, we generated germline transgenic mouse lines overexpressing human TARDBP (TDP43 WT ). We show here that overexpression of WT TDP-43 leads to degeneration of specific neurons in the central nervous system, including spinal and cortical motor neurons and nonmotor cortical neurons characteristically affected in FTLD-TDP, and causes spastic quadriplegia in a dosedependent manner.
Results

Dose-Dependent Motor Neuron Disease in TDP43
WT Mice. We generated several germline transgenic mouse lines overexpressing human wild-type TARDBP (TDP43 WT ) under the control of a neuronal murine Thy-1 (mThy-1) promoter that drives transgene expression in virtually all neurons of the central nervous system (Fig. 1A ) and becomes active approximately 1 week after birth (16) . Transgene levels in total brain lysates were analyzed by semiquantitative real-time PCR (Q-RT-PCR) (Fig. 1B) and immunoblotting with anti-TDP-43 antibodies (Fig. S1 ). In none of the TDP43
WT lines did TDP-43 expression exceed 1× endogenous TDP-43 expression. To increase transgene dose, we generated homozygous mice from the two highest-expressing founder lines. Homozygous TAR4/4 and TAR6/6 lines showed a double transgene expression (2× and 1.2×, respectively) compared with hemizygous TAR4 and TAR6 lines with 1× and 0.6× hTDP-43 levels over endogenous protein levels (Fig. 1B and Fig.  S1 ). Because Thy-1 expression is limited to neurons, we also analyzed hTDP-43 expression relative to murine TDP-43 by Q-RT-PCR in neurons isolated from 1-month-old TDP43 WT mice (17) , and also by immunohistochemical densitometric quantification (18) (Fig. S1 ). On ≈5-fold-enriched neuronal preparations, TAR4 and TAR6 mice showed 1.4-fold and 0.9-fold Author contributions: H.W., C.V.B., and S.K.-S. designed research; H.W., G.K., J.J., S.P., G.J., I.C., V.S., and S.K.-S. performed research; C.C.-d.G. contributed new reagents/analytic tools; H.W., G.K., J.J., S.P., and S.K.-S. analyzed data; and H.W., C.V.B and S.K.-S. wrote the paper.
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This article contains supporting information online at www.pnas.org/cgi/content/full/ 0912417107/DCSupplemental. hTDP-43 over murine TDP-43. Image densitometry of neuronal TDP-43 staining by a non-species-specific TDP-43 antibody further confirmed that TAR4 and TAR6 had 2.8-and 1.9-fold, and homozygous TAR4/4 and TAR6/6 had 5.1-and 3.8-fold hTDP-43 expression, compared with murine TDP-43 in nontransgenic (Ntg) mice (Fig. S1 ).
Homozygous TDP43 WT mouse lines were morphologically indistinguishable from their hemizygous or Ntg littermates at birth. At ≈14 days, TAR4/4 mice developed an abnormal hindlimb reflex characterized by retraction of hindlegs toward the trunk upon lifting them by their tail, as opposed to Ntg littermates, which showed normal extension of the legs (Fig. 1C) . This reflex was demonstrated as one of the earliest symptoms of loss of motor control in several ALS mouse models (19) . A footprint analysis for TAR4/4 mice showed a significant ≈2-fold decrease in the stride of hindlimbs (1.5 ± 0.26 cm vs. 3.4 ± 0.32 cm; P = 0.025) and of forelimbs (1.5 ± 0.19 cm vs. 3.3 ± 0.41 cm; P < 0.01). Moreover, footprints of TAR4/4 mice were characterized by separated forelimb and hindlimb prints, markedly wide-based stance, small stride, and frequent off-line stumbling compared with Ntg littermates, which showed a normal, narrow-based stance with steady, close-proximity forelimb and hindlimb footprints ( Fig. 1 E and F) . When tested for motor performance on accelerating rotarod, 18-day-old TAR4/4 mice showed a statistically significant ≈2.5-fold reduced performance compared with Ntg littermates (114.2 ± 51.10 s vs. 236.2 ± 31.47 s; P < 0.01) (Fig. 1G) . At ≈22 days, fasciculations and spasms of facial muscles were also observed, which was followed by an extremely rapid disease progression, with mice becoming completely paralyzed and dying within 3-4 days ( Fig. 1 H and I and Movie S1).
To verify that the hTDP-43 construct did not cause insertional mutagenesis of a mouse endogenous gene leading to the observed phenotype, we characterized the transgene integration site in the TAR4 mouse line. A thermal asymmetric interlaced PCR analysis showed that hTDP-43 had integrated at locus 6qB3 of the mouse genome (nucleotide no. 56,524,796; UCSC Genome Browser, http://www.genome.ucsc.edu/) and did not interrupt any known gene.
Subsequently, motor problems also developed in TAR6/6 and TAR4 mice (Table S1 ). TAR6/6 mice developed abnormal limb reflex at 2 months, showed up to 6-fold reduced motor performance at ≈4 months (P < 0.01; Fig. S2 ), and an average survival of 6.7 months (Fig. 1I) . Similarly, TAR4 mice showed abnormal limb reflex at ≈14 months and 40% reduced motor performance at ≈15 months of age (P < 0.01; Fig. S2 ). Thus, correlation of hTDP-43 expression in TAR4/4, TAR6/6, and TAR4 mice with age of disease onset was best explained by a loglog regression model (correlation coefficient R 2 = 0.98; P < 0.001; Fig. 1D (4, 5, 20) . We therefore first examined brains of TAR4/4, TAR6/6, and TAR4 mice by ubiquitin immunohistochemistry. Despite mThy-1 promoter driving transgene expression in virtually all neurons of the brain, dense, large NCIs and NIIs characteristic of FTLD and ALS patients were present solely in cortical layer V of the anterior cortex, including primary motor cortex and somatosensory areas of the hind-and forelimbs, and also to some extent in hippocampal/subicular neurons ( Fig. 2 A-C and Fig. S3 ). A dosedependent, diffuse ubiquitin immunostaining was also present in brainstem, cranial motor nuclei, and Purkinje cells, but was absent from other brain regions, including neostriatum, substantia nigra, and thalamus. Using a panel of TDP-43-specific antibodies, including phosphospecific TDP-43 antibodies (21), we further showed that though NIIs always costained for TDP-43, a proportion of NCIs did not stain with TDP-43 antibodies ( Fig. 2 B and C). The presence of NCIs, and to some extent NIIs, also coincided with an overall decreased nuclear TDP-43 reactivity, or "clearing," as described for ALS and FTLD patients (4, 5) .
Interestingly, dose-dependent astrogliosis and microgliosis were also observed in TAR4/4, TAR6/6, and TAR4 mice in the same regions where NCIs, NIIs, and diffuse cytoplasmic ubiquitin staining was observed (Fig. S4 ). For TAR4/4, glial fibrillary acidic protein (GFAP) selectively stained cortical layer V of the anterior cortex, including the motor and somatosensory cortex (Fig. 2D ). Neuronal loss was also present in affected brain regions of all mouse lines in both superficial and deep cortical layers of the anterior cortex, especially in higher-expressing TAR4/4 and TAR6/6 mice. Quantitative neuronal loss was shown in motor cortex of TAR4/4 mice compared with Ntg littermates at 24 days (867 per mm 2 ± 195 vs. 1,231 ± 181; P < 0.001) and of TAR6/6 mice at 6 months (969 ± 187 per mm 2 vs. 1,149 ± 185; P < 0.01; Fig. 2E and Fig. S3 ). Vacuolar degeneration of several cranial motor nuclei was also observed, especially for the highest-expressing TAR4/4 line. In addition, TAR4/ 4 mice showed loss of CA3 hippocampal neurons and degeneration of Purkinje cells. These data are consistent with mutant superoxide dismutase 1 (SOD1) mice, where in low doses, the spinal cord is primarily affected, and in higher doses, other regions are also affected (22, 23) . Moreover, a preferentially higher expression of hTDP-43 is shown to occur in the hippocampus (24) , and degeneration of susceptible hippocampal cellular population is commonly observed in FTLD-TDP patients (25) . Cerebellum is also shown to be severely affected in ALS patients (26) . Thus, TDP43
WT mice recapitulate FTLD/ALS pathology, including the characteristic NCIs and NIIs. Interestingly, these pathological changes were accompanied by increased levels of activated caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP) (Fig. S5) , additionally suggesting that neuronal apoptosis is a hallmark of TDP-43 proteinopathies.
Because TAR4/4, TAR6/6, and TAR4 mice also showed an ALS phenotype, we next focused our attention on the spinal cord of these TDP43
WT mice ( Fig. 3 and Fig. S3 ). Atrophy and increased number of pyknotic neurons in the ventral horn region of the lumbosacral and cervical spinal cord occurred in all three transgenic mouse lines with a severity that was highly dosedependent. For TAR4/4 and TAR6/6 mice, although all spinal segments were affected, loss of the characteristic cervical and lumbosacral enlargements that innervate the extremities was remarkable. The number of neurons in the lumbosacral region in TAR4/4 mice was significantly lower than in Ntg littermates (608 ± 112 vs. 803 ± 125 per mm 2 ; P < 0.001) as was also observed in TAR6/6 mice (689 ± 107 vs. 768 ± 108 per mm 2 ; P < 0.05; Fig.   3H and Fig. S3 ). Further using ubiquitin immunohistochemistry, a dose-dependent accumulation of ubiquitinated proteins in spinal motor neurons was also observed for all lines, shown here for TAR4/4 mice (Fig. 3A) . Employing phosphospecific TDP-43 antibodies that can recognize pathological TDP-43, we showed a punctate staining pattern of the nucleus and cytoplasm in ≈10%, ≈2%, and less than 1% of spinal neurons in TAR4/4, TAR6/6, and TAR4 mice, respectively. TAR4/4 mice also showed larger cytoplasmic aggregates as granulovacuolar bodies. More interestingly, NIIs of 2-2.5 μm in diameter were observed in ≈1% of spinal neurons in 22-to 24-day-old TAR4/4 mice, but not in 18-day-old or younger TAR4/4 or in other mouse lines (Fig. 3 B-D) . The presence of NIIs was also accompanied by nuclear TDP-43 clearing. Transmission electron microscopy confirmed light microscopy data by showing presence of non-membrane-bound NIIs of 2-3 μm in diameter, composed of loosely packed granular material and 10-to 20-μm fibrils, and was also accompanied by neuritic changes (Fig. 3 E and F) as shown in ALS and FTLD patients (27, 28) . Similar to GFAP staining in the motor cortex, neuronal inclusions were also marked by astrogliosis (Fig. 3G) . In none of the mouse models at any disease stage did the NIIs or NCIs in brain or spinal cord stain for tau or α-synuclein, which are important exclusion criteria for TDP-43 proteinopathies.
Accumulation of Detergent-Soluble ≈25-kDa CTFs in Nuclear Fraction.
Another characteristic feature of FTLD and ALS is accumulation of ≈25-kDa CTFs in affected brain and spinal cord regions (4, 5, 29) . We thus characterized TDP-43 CTFs from brain of different TDP43
WT mice and different disease stages of TAR4/4 mice by immunoblotting with a panel of TDP-43 antibodies. Also, because TDP-43 has important nuclear functions, we analyzed the cytoplasmic and nuclear fractions separately. We first showed hTDP-43 full-length (FL) protein in both nuclear and cytoplasmic fractions; however, compared with Ntg mice, TAR4/4 mice showed increased levels of TDP-43 in the cytoplasmic fraction, whereas in the nuclear fraction, FL TDP-43 levels did not differ between TAR4/4 and Ntg mice (Fig. 4A and  Fig. S6 ). These data suggest that levels of FL TDP-43 in the nucleus are tightly regulated. Similar observations were also made on TAR6/6 mice. Reprobing these blots revealed lamin A/ C detection only in the nuclear fraction and GAPDH only in the cytoplasmic compartment, confirming a clear separation of nuclear and cytoplasmic fractions (Fig. 4A Lower) . The ≈35-kDa CTFs were also recovered from both cytoplasmic and nuclear fractions from TDP43 WT mice but not from Ntg littermates. When analyzing different disease stages of TAR4/4 mice, the ≈35-kDa CTF levels decreased with increasing disease severity ( Fig. 4A and Fig. S6 ). The identity of these fractions was also confirmed by immunoblotting with a C-t antibody (30) (Fig. 4B) . Finally, the ≈25-kDa fragment was also specifically observed in TDP43 WT mice but only in the nuclear fraction, and increased with increasing disease severity in TAR4/4 mice (P < 0.001; Fig.  4B ). These data suggest that ≈25-kDa TDP-43 fragments play a pathogenic role in these mouse models.
Because decreased solubility of TDP-43 or its cleaved fragments is also proposed as a disease mechanism (4, 5), we further determined the solubility of TDP-43 by sequential brain extraction with buffers of increasing detergent strengths (31) . Though the majority of ≈35-kDa CTFs were recovered in low-salt (LS) fraction, and to some extent in Triton X-100 (Tx) fraction, FL TDP-43 was recovered from LS, Tx, sarkosyl-soluble (SARK), and, in a very small proportion, from the detergent-insoluble (urea) fraction. However, the ≈25-kDa CTFs were recovered solely in the Tx fraction that also solubilized nuclear lamin A/C protein (Fig. 4C) . Interestingly, though presence of ≈25-kDa CTFs in the detergent-insoluble urea fraction is a hallmark feature of TDP-43 proteinopathy, these CTFs are also consistently recovered in the Tx-soluble nuclear fractions from brains of FTLD/ALS patients ( Fig. 4D and Fig. S7 ). Because ≈25-kDa CTFs lack the predicted NLS sequence (6-9), we tested whether this hinders their transport to nucleus. Transiently transfecting two human cell lines (SH-SY5Y neuron-like cells and H4 neuroglioma cells) with a caspase-cleaved, GFP-tagged, TDP-43 CTF construct (TDP-43-Δ1-219-GFP) (32), we showed a predominant nuclear localization of this fragment (Fig. 4E) . These data all indicate that ≈25-kDa CTFs can localize to the nucleus and progressively deposit in affected brain and spinal cord regions and associate with the phenotype we describe here, and is consistent with the idea that ≈25-kDa CTFs play a direct role in TDP-43-led neurodegeneration (4, 5, 29) .
Discussion
Abnormal aggregation of proteins into fibrillar lesions is a neuropathological hallmark of several sporadic and hereditary neurodegenerative diseases, such as Alzheimer's disease, Parkinson disease, and Huntington disease (33) . However, it is unclear whether it is the abnormal sequestration of protein in these aggregates or if they form the reservoir for the formation of low molecular weight oligomers as shown for a number of neurodegenerative diseases (33, 34) . Identification of TDP-43 as a major ubiquitinated protein in FTLD-TDP and ALS patients has also led to a similar intense investigation into whether TDP-43 mediated neurodegeneration is through a gain of one or more toxic properties of the aggregates or a loss of normal TDP-43 function arising from sequestration of the normal protein in cellular aggregates (14, 29, 35, 36) .
We report here a unique mouse model of TDP-43 developing large NCIs in vulnerable neurons characteristic of FTLD and ALS as well as NIIs characteristic of FTLD-TDP. The NIIs were almost always composed of ubiquitinated and phosphorylated TDP-43, and development of these inclusions coincided with the extremely rapid progression of disease in the TAR4/4 line. Thus, it remains possible that formation of NIIs contributed significantly to the disease progression. The NCIs in TDP43 WT mice also contained phosphorylated and ubiquitinated forms of TDP-43; however, in many such inclusions, TDP-43 was not the major ubiquitinated protein deposited. These data suggest that TDP-43 might trigger dysfunction of protein degradation pathways, such as the ubiquitin proteasome system and authophagy, which is a hallmark feature of neurodegenerative diseases (37) .
Toxicity incurred by 22-to 25-kDa TDP-43 CTFs was proposed as a disease mechanism in sporadic ALS and FTLD patients (4, 5, 29) . In support of these findings, we report here the generation and accumulation of ≈25-kDa TDP-43 CTFs in TDP43 WT mice that correlated with the disease progression in the TAR4/4 mouse line. Surprisingly, the ≈25-kDa CTFs were recovered from the nuclear compartment and not from the cytoplasm. Though the ≈25-kDa fragment importantly contains the conserved ribonucleoprotein RNP2 segment shown to bind to the TAR DNA sequence and RNA sequences with UG repeats involved in various TDP-43 functions, it lacks the nuclear localization signal (NLS) (6-9, 38). However, one of the shortest 25-kDa caspase-derived TDP-43 CTFs (TDP-43-Δ1-219) (32) despite lacking the NLS, predominantly localized to the nucleus when expressed in two human cell lines. X-ray crystallography data has shown that TDP-43 exists as a dimer, and the RRM2, of which the RNP2 is a part, is important in the β-strand and TDP-43 dimeric structure formation (39) . Whether the ≈25-kDa CTFs are passively transported to the nucleus where it binds to endogenous TDP-43 or other targets, or is transported to nucleus in a dimeric state with full-length TDP-43, remains to be shown.
Recently, a mouse model of an ALS-associated mutant form of human TDP-43 driven by a mouse PrP promoter (PrP-TDP43 A315T ) has been described where a 3-fold transgene overexpression leads to features of ALS and FTLD with average survival of ≈5 months (40) . PrP-TDP43
A315T mice develop gait WT and probably related to transgene dose, interestingly, PrP-TDP43
A315T also accumulated ≈25-kDa CTFs in brain and spinal cord. Though Wegorzewska and co-workers (40) were unable to generate Prp-TDP-43 wild-type mice, we show here that ≈2.8-fold total TDP-43 neuronal expression in Thy-1 driven TDP43
WT mice is toxic to neurons, and ≈3.8-fold TDP-43 neuronal expression leads to mortality at ≈6 months. Though it is difficult to compare the relative toxicity of WT TDP-43 versus A315T mutant because PrP promoter drives expression in both neurons and glial cells, and the relative expression of endogenous TDP-43 in neurons and glial cells is unknown, it is clear that expression of TDP-43 is less well tolerated in mice compared with mutant SOD1 (mSOD1). For instance, at least two commonly used mSOD1 mouse lines have mutant protein accumulating to ≈10× levels over the already abundant endogenous SOD1 (22, 23) . Also, TDP-43 dose is related to specific vulnerability of select neurons, as Thy-1 promoter driven expression is one of the highest in the dentate gyrus cells (24)-neurons that were not typically affected in the TDP-43 WT mice.
Finally, the fact that both overexpression of WT TDP-43 and an ALS mutant lead to similar disease in transgenic mice and an increase of ≈25-kDa TDP-43 fragments importantly suggests that TARDBP mutations identified in ALS patients likely act by a gain-of-function mechanism. Given the toxic effect of TDP-43 protein or its fragments, it is less likely that copy-number variations will be identified in ALS/FTLD patients; however, polymorphisms within the TARDBP 3′ UTR region have been identified that increase TDP-43 levels (41). Although a further genetic proof of TDP-43 dosage in ALS/FTLD is needed, interestingly, Wobbler mouse models of ALS due to mutation in the Vps54 gene show up-regulation and accumulation of TDP-43 in brain (42, 43) . Our data thus importantly suggest that targeting TDP-43 accumulates might be one therapeutic option in ALS-FTLD spectrum disorders involving TDP-43.
Note that while this paper was under review, a report on a TDP-43 knockout mouse model was published showing that heterozygous mice are phenotypically normal and without obvious motor-function defect (44) .
Materials and Methods
Construction of Transgenic Mice Expressing Wild-Type Human TDP-43. TARDBP (NM_007375) was amplified from a human cDNA library (hTDP-43) and cloned into an mTUB expression vector containing a murine Thy-1 promoter (JSW Research). The expression vector was microinjected into pronuclear oocytes of Bl6/SJL mice by the Yale Transgenic Mouse Service Facility (New Haven, CT). Offspring were genotyped, and from 108 potential transgenic pups, 23 were identified to carry the transgene. Founders were bred with Ntg C57Bl6/J mice to establish stable transgenic lines. Additionally, homozygous hTDP-43-overexpressing mice were generated for two selected lines by crossbreeding hemizygous hTDP-43-overexpressing mice. Homozygosity was determined by semiquantitative PCR, and homozygous expression was confirmed by Q-RT-PCR and immunoblotting on brain tissue of 3-week-old mice. Although homozygous hTDP-43 mice were generated each time by crossbreeding of hemizygous mice, for sake of convenience, homozygous mice are also referred to as mouse lines. All animal experiments were approved by the University of Antwerp Ethics Committee and conducted according to the guidelines of the Federation of European Laboratory Animal Science Associations (FELASA).
Analysis of Integration Site. Thermal asymmetric interlaced (TAIL) PCR was performed to define the hTDP-43 chromosomal integration site essentially as described previously (45) . Following TAIL-PCR, products were directly sequenced, and the specific chromosomal integration sites were identified using the UCSC BLAST database for Mus musculus genomic DNA (http:// www.genome.ucsc.edu/, assembly: July 2007).
Tissue Preparation. Brains were harvested, weighed, and cut midsagittally. Left hemispheres were fixed in 2% paraformaldehyde (18-20 h) or 4% glutaraldehyde (4 h) and further prepared for histological or electron microscopy analysis, respectively. Right hemispheres were snap frozen in liquid nitrogen and stored at −80°C for subsequent mRNA and protein analysis. Similarly, spinal cords subdivided into cervical, thoracic, lumbar, and sacrococcygeal regions were also processed as described for brain.
Immunoblotting. Cytoplasmic and nuclear fractions from brain were prepared as described earlier (46) . Briefly, frozen tissue was weighed and homogenized in buffer containing 10 mM Hepes, 10 mM NaCl, 1 mM KH 2 PO 4 , 5 mM NaHCO 3 , 5 mM EDTA, 1 mM CaCl 2 , 0.5 mM MgCl 2 (10× vol/wt). After 10 min on ice, 2.5 M sucrose (0.5× vol/wt) was added. Next, tissue was homogenized and centrifuged at 6,300 × g for 10 min. The supernatant was collected as cytoplasmic fraction. The pellet was washed three times in TSE buffer (10 mM Tris, 300 mM sucrose, 1 mM EDTA, 0.1% Nonidet P-40, 10× vol/wt), homogenized, and centrifuged at 4,000 × g for 5 min. Finally the pellet was resuspended in RIPA with 2% SDS (5× vol/wt) as the nuclear fraction.
Also, proteins were sequentially extracted with buffers of increasing detergent strength (hypotonic, Triton X-100, myelin floatation, sarkosyl, and urea buffers) as described previously (31) . All buffers were substituted with protease inhibitors (Complete Mixture; Roche) and phosphatase inhibitors (PhosphoStop; Roche) before use. The following antibodies were used: rabbit anti-TDP-43 (ProteinTech Group), human specific mouse anti-TDP-43 (against residues 205-222; Abnova), rabbit anti-C-terminal TDP-43 (C-t TDP- Fig. S6 ). Approximately 35-kDa CTFs are decreased with increasing disease severity in both nuclear and cytoplasmic fractions (Fig. S6) , whereas the ≈25-kDa CTFs were only recovered from the nuclear fraction and correlated with disease progression. GAPDH was used as a marker for the cytoplasmic fraction and lamin A/C for the nuclear fraction. Asterisk at ≈34 kDa likely represents a known splice form of endogenous mouse TDP- 
